A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD) compared to the current non-small cell therapy, which is significant in the EFRT treatment. However, resistance causes recurrence in most patients. Therefore, it is necessary to develop a more effective treatment. Recently, in Japan, combined allotinib and bevacizumab therapy as primary therapy in non-small cell lung cancer patients with EGFR mutation improved PFS statistic

Trial Details

NCT ID
NCT06156527
Phase
PHASE2
Sponsor
National Cancer Center, Korea
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Lazertinib
  • Bevacizumab Injectable Product
Locations (sample)
  • Suwon, Gyeonggi-do, South Korea|37.29111,127.00889
  • Goyang-si, Gyeunggi-do, South Korea|37.65639,126.835
  • Suwon, Gyeunggi-do, South Korea|37.29111,127.00889
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Histologically confirmed patients with locally progressive or metastatic non-small cell lung cancer (IIIB or IV) who have not been diagnosed as squ…
  • Patients with one or more measurable lesions in accordance with the RECIST criteria (Version 1.1), tumor lesions located at the previous irradiatio…
  • Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)
  • Patients with a history of smoking, including those who are currently smoking (defined as those who have smoked more than 100 cigarettes in their l…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →